Lepu Biopharma Co., Ltd. (HKG:2157)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.260
-0.070 (-1.62%)
May 28, 2026, 10:10 AM HKT
Market Cap7.81B -6.4%
Revenue (ttm)1.04B +154.2%
Net Income290.85M
EPS0.17
Shares Out 1.80B
PE Ratio26.13
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume760,000
Open4.450
Previous Close4.330
Day's Range4.240 - 4.450
52-Week Range3.900 - 10.500
Beta-0.41
Analystsn/a
Price Targetn/a
Earnings DateMar 25, 2026

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; CMG901 CLDN18.2-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 710
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2157
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements